Navigation Links
ChromaDex® Announces Letter of Intent Signed with Glanbia Nutritionals for Partnership on pTeroPure®
Date:1/24/2012

IRVINE, Calif., Jan. 24, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of its branded patent-pending pterostilbene, pTeroPure, announced today it has signed a letter of intent with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company, for the distribution of pTeroPure. Glanbia Nutritionals will serve as the primary distributor of pTeroPure in North America.

pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan, and is the central ingredient in its recently launched BluScience™ line of dietary supplements.

pTeroPure is a proprietary, nature-identical formulation of the antioxidant compound pterostilbene, which is found naturally in blueberries. Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other polyphenols (an antioxidant phytochemical that tends to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging. However, the amount of pterostilbene present in a typical serving of blueberries is a tiny fraction of the amount needed to realize its benefits. In fact, one BluScience capsule has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.

"Partnering with a large, exceptionally strong company like Glanbia is a tremendous next step in expanding pTeroPure's adoption into numerous consumer products. With our upcoming human clinical data release and our various patents pending, in combination with Glanbia's strong distribution base, we are now very well-positioned to more rapidly accelerate our national expansion of pTeroPure," said William Spengler, President of ChromaDex.

"ChromaDex's pTeroPure is an excellent addition to our product portfolio due to its superior bioavailability and range of potential health benefits," said Richard Hazel, CEO of Glanbia Nutritionals (NA), Inc. "The new distribution agreement will allow us to utilize our extensive market experience and national sales resources towards promoting ChromaDex's innovative new product line and will benefit Glanbia Nutritionals by strengthening our position as a leader in the ingredients industry."

About Glanbia Nutritionals (NA), Inc.:

Glanbia Nutritionals is a division of Glanbia plc, an international nutritional solutions and cheese group, headquartered in Kilkenny, Ireland. The Group has 4,300 employees worldwide, with operations in Ireland, the UK, Germany, USA, Canada, Mexico and China, as well as strategic international joint ventures in the UK, USA and Nigeria. Glanbia is listed on both the Dublin and London Stock Exchange. Glanbia is a global supplier of nutritional ingredients, functional ingredients and customized premix solutions. Glanbia Nutritionals is on the forefront in the exploration of science and the dynamics that drive the growing nutrition industry. For more information visit glanbianutritionals.com or contact Thomas Monroe, Marketing, 760-438-0089, tmonroe@glanbia.com.

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its BluScience™ line of dietary supplements, now available at Drugstore.com. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets, among others. pTeroPure is currently being studied in a human clinical trial at the University of Mississippi.

For more information about pTeroPure visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Contact:

Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

Institutions and Analysts Contact:

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

pTeroPure® Contact:

Jeremy Bartos
ChromaDex Product Development
949-600-9694
jeremyb@pteropure.com

*These statements have not been evaluated by the Food and Drug Administration.  This product is not intended to diagnose, treat, cure or prevent any disease.

 


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ChromaDex®s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... 2017 Lo stesso sistema sara, visibile nello stand a ... Paramed Medical Systems sta installando la settima unità MROpen in Gran Bretagna, ... centro dell,European Scanning Center (ESC) a Cardiff. ESC attualmente gestisce altri due sistemi ... Continue Reading ... ...
(Date:2/28/2017)... , Feb. 28, 2017 Mechanical Ventilators ... full report: https://www.reportbuyer.com/product/4402626/ This report ... on the global and regional levels. It provides historical ... 2024 in terms of revenue (US$ Mn) and volume ... an outlook on mechanical ventilators sales globally. It includes ...
(Date:2/28/2017)... Feb. 28, 2017 Intraocular Lens Market: Overview ... ... eye disease characterized by cloudiness / opaqueness of the natural ... if not treated leads to permanent loss of vision. Intraocular ... for the treatment of cataract. Cataract is considered as one ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... The Industrial Designers Society of America (IDSA) ... awareness of the profession of industrial design (ID) and relaunching "What Is ID?" ... school students and counselors; parents; and the greater public. , Share details and photos ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... to announce the release of its 2017 update to Compass, the popular ... and physician advisors. , Suitable for standardizing both new-hire on-boarding and annual ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Grund® America ... Towels and Bath Rugs launching at the March 2017 International Housewares Show in Chicago ... rugs, which are made with the highest quality,100% OEKO-TEX and GOTS Organic Cotton material. ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... increase colorectal cancer screening rates by supporting the 80% by 2018 initiative, led ... (CDC) and the National Colorectal Cancer Roundtable (an organization co-founded by ACS and ...
(Date:3/1/2017)... ... March 01, 2017 , ... MilfordMD Cosmetic Dermatology ... month of March for treatments aimed at tightening skin and contouring the neck. ... skin tightening, with 30 percent off all Thermage face and body treatments. March ...
Breaking Medicine News(10 mins):